Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 4

1.

Nelfinavir and its active metabolite, hydroxy-t-butylamidenelfinavir (M8), are transferred in small quantities to breast milk and do not reach biologically significant concentrations in breast-feeding infants whose mothers are taking nelfinavir.

Weidle PJ, Zeh C, Martin A, Lando R, Angira F, Osoga J, Ogindo P, Girde S, Minniear TD, Thomas TK.

Antimicrob Agents Chemother. 2011 Nov;55(11):5168-71. doi: 10.1128/AAC.05273-11. Epub 2011 Aug 29.

2.

Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation.

van 't Klooster G, Hoeben E, Borghys H, Looszova A, Bouche MP, van Velsen F, Baert L.

Antimicrob Agents Chemother. 2010 May;54(5):2042-50. doi: 10.1128/AAC.01529-09. Epub 2010 Feb 16.

3.

Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.

Hirt D, Urien S, Jullien V, Firtion G, Chappuy H, Rey E, Pons G, Mandelbrot L, Treluyer JM.

Br J Clin Pharmacol. 2007 Nov;64(5):634-44. Epub 2007 Sep 24.

4.

Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.

Hirt D, Urien S, Jullien V, Firtion G, Rey E, Pons G, Blanche S, Treluyer JM.

Antimicrob Agents Chemother. 2006 Mar;50(3):910-6.

Supplemental Content

Support Center